Francis deSouza has resigned as CEO and director of Illumina after recently surviving activist investor Carl Icahn’s proxy fight against the company, which involved demands to remove deSouza from the DNA sequencing company’s board and replace him as chief executive.

After three delays, Catalent has finally released its quarterly earnings. In the end, the news wasn’t nearly as bad as expected. The CDMO giant, which has been plagued by major production problems at three of its sites, has made a slight adjustment to its revenue projection, which is expected to come in at between $4.23 billion and $4.33 billion as opposed to a previous projection window of $4.25 billion to $4.35 billion.

No more beating around the bush here: With a newly bestowed FDA clearance, Huma’s disease-agnostic health management software can now be more direct in offering clinical recommendations to users and their doctors.

A week after Oncorus shed pretty much all its staff, the board has decided that the game is up and moved to liquidate the RNA-focused company.

The drugmaker will defend itself against claims from a German healthcare worker who sued the company for at least 150,000 euros ($161,500). The plaintiff alleges she suffered bodily harm resulting from Pfizer and BioNTech's Comirnaty vaccine.